DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

Information source: Indiana University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Kidney Disease; Endothelial Dysfunction; Inflammation; Hypertension

Intervention: paricalcitol (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Indiana University School of Medicine

Official(s) and/or principal investigator(s):
Rajiv Agarwal, MD, Principal Investigator, Affiliation: Indiana University School of Medicine

Summary

The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the kidney and cause damage to the kidney. The purpose of this study is to determine if paricalcitol helps improve kidney injury, blood pressure control and kidney function in patients with chronic kidney disease. The study will last about 7 weeks and involves about 8 visits to the medical center.

Clinical Details

Official title: Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

Anti-Inflammatory Effects of Paricalcitol

Endothelial Protectant Effects of Paricalcitol

Secondary outcome:

Effect of Paricalcitol on Hypertension

Effect of Paricalcitol on Kidney Function

Detailed description: We hypothesize that use of paricalcitol in patients with chronic kidney disease will lead to improvement in oxidative stress, inflammation, endothelial function and subsequently ambulatory blood pressures and glomerular filtration rate. We will pursue our hypothesis by the three specific aims: Aim 1: To compare oxidative stress markers in patients treated with paricalcitol before and after the study. Aim 2: To measure endothelial function by flow mediated dilation in patients with chronic kidney disease before and after paricalcitol. Aim 3: To measure actigraphy guided ambulatory blood pressure and GFR in the absence of changes in anti-hypertensive medications in patients with chronic kidney disease. The study will be double blind randomized pilot trial in 24 patients with chronic kidney disease with 1: 1:1 allocation to paricalcitol 1 microgram: paricalcitol 2 microgram: Placebo.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with chronic kidney disease with estimated GFR of 30 mL/minute or more.

- Patients receiving stable dose of ACE inhibitor or Angiotensin receptor blockers for

at least one month.

- Patients not currently hypertensive more than 180/110 mmHg by clinic blood pressure.

- Hemoglobulin A1C< 11%

Exclusion Criteria:

- Patients taking vitamin D analogs

- Calcium> 10 mg/dL

- Phosphorus>6 mg/dL

- Patients with anticipated need of dialysis in the next 6 weeks

- Patients unstable in the opinion of the investigator

- Patients who have emergent need for starting IV iron

- Patients who will be started on statins within the next 6 weeks

- Patients currently taking PDE5 inhibitors

- Patients allergic to radiocontrast, Zemplar or who can not take nitroglycerin

- Patients known to be HIV positive

- Patients who can not give informed consent

Locations and Contacts

Richard A. Rodebush VA Medical Center, Indianapolis, Indiana 46202, United States
Additional Information

Starting date: November 2006
Last updated: April 6, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017